Straits Times Index
3,294.91 +22.19 (+0.68%) Nikkei
38,407.90 +855.74 (+2.28%) Hang Seng
17,110.21 +281.28 (+1.67%) FTSE 100
8,044.81 +20.94 (+0.26%) Bitcoin USD
66,968.55 +622.28 (+0.94%) CMC Crypto 200
1,443.63 +28.87 (+2.04%)
Vanda Pharmaceuticals Inc. (VNDA)
After hours:
| Previous close | 4.8000 |
| Open | 4.7600 |
| Bid | 4.5800 x 100 |
| Ask | 4.6500 x 600 |
| Day's range | 4.6200 - 4.8700 |
| 52-week range | 3.3000 - 7.0000 |
| Volume | |
| Avg. volume | 2,350,987 |
| Market cap | 266.399M |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 115.75 |
| EPS (TTM) | 0.0400 |
| Earnings date | 01 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.25 |
PR NewswireVanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ® Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp.
- Reuters
UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling by the patent-focused U.S. Court of Appeals for the Federal Circuit against the company, which in 2018 had sued Teva and Apotex in Delaware for patent infringement after they applied to make generic versions of Vanda's Hetlioz, a circadian-rhythm drug used to treat rare sleep disorders.
ReutersU.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
WASHINGTON (Reuters) -The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling by the patent-focused U.S. Court of Appeals for the Federal Circuit against the company, which in 2018 had sued Teva and Apotex in Delaware for patent infringement after they applied to make generic versions of Vanda's Hetlioz, a circadian-rhythm drug used to treat rare sleep disorders.
